404 related articles for article (PubMed ID: 37561223)
1. Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials.
Meifang W; Ying W; Wen C; Kaizu X; Meiyan S; Liming L
Heart Fail Rev; 2024 Mar; 29(2):305-320. PubMed ID: 37561223
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction.
Peters AE; DeVore AD
Cardiol Clin; 2022 Nov; 40(4):473-489. PubMed ID: 36210132
[TBL] [Abstract][Full Text] [Related]
3. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
[TBL] [Abstract][Full Text] [Related]
4. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
Merrill M; Sweitzer NK; Lindenfeld J; Kao DP
JACC Heart Fail; 2019 Mar; 7(3):228-238. PubMed ID: 30819379
[TBL] [Abstract][Full Text] [Related]
5. Management of Heart Failure With Preserved Ejection Fraction in Elderly Patients: Effectiveness and Safety.
Elkammash A; Tam SSC; Yogarajah G; You J
Cureus; 2023 Feb; 15(2):e35030. PubMed ID: 36938226
[TBL] [Abstract][Full Text] [Related]
6. What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence.
Sevre K; Rist A; Wachtell K; Devereux RB; Aurigemma GP; Smiseth OA; Kjeldsen SE; Julius S; Pitt B; Burnier M; Kreutz R; Oparil S; Mancia G; Zannad F
Am J Hypertens; 2024 Jan; 37(1):1-14. PubMed ID: 37551929
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
Mentz RJ; Brunton SA; Rangaswami J
Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
[TBL] [Abstract][Full Text] [Related]
8. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.
Anker SD; Butler J; Filippatos G; Shahzeb Khan M; Ferreira JP; Bocchi E; Böhm M; Brunner-La Rocca HP; Choi DJ; Chopra V; Chuquiure E; Giannetti N; Gomez-Mesa JE; Janssens S; Januzzi JL; Gonzalez-Juanatey JR; Merkely B; Nicholls SJ; Perrone SV; Piña IL; Ponikowski P; Senni M; Seronde MF; Sim D; Spinar J; Squire I; Taddei S; Tsutsui H; Verma S; Vinereanu D; Zhang J; Jamal W; Schnaidt S; Schnee JM; Brueckmann M; Pocock SJ; Zannad F; Packer M;
Eur J Heart Fail; 2020 Dec; 22(12):2383-2392. PubMed ID: 33251670
[TBL] [Abstract][Full Text] [Related]
9. Medical Therapies for Heart Failure With Preserved Ejection Fraction.
Kjeldsen SE; von Lueder TG; Smiseth OA; Wachtell K; Mistry N; Westheim AS; Hopper I; Julius S; Pitt B; Reid CM; Devereux RB; Zannad F
Hypertension; 2020 Jan; 75(1):23-32. PubMed ID: 31786973
[TBL] [Abstract][Full Text] [Related]
10. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
[TBL] [Abstract][Full Text] [Related]
11. Current Updates in the Pharmacotherapy of Heart Failure with a Preserved Ejection Fraction.
Dahal R; Nickel N; Mukherjee D; Alkhateeb H
Cardiovasc Hematol Disord Drug Targets; 2022; 22(2):87-95. PubMed ID: 35786196
[TBL] [Abstract][Full Text] [Related]
12. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
Tromp J; Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Køber L; Swedberg K; Zile MR; Pitt B; Lam CSP; McMurray JJV
J Am Coll Cardiol; 2019 Aug; 74(5):601-612. PubMed ID: 31370950
[TBL] [Abstract][Full Text] [Related]
13. Use of Sodium-Glucose Cotransporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real-World Data.
Alonso A; Morris AA; Naimi AI; Alam AB; Li L; Subramanya V; Chen LY; Lutsey PL
J Am Heart Assoc; 2024 Mar; 13(6):e032783. PubMed ID: 38456406
[TBL] [Abstract][Full Text] [Related]
14. Obesity-related heart failure with preserved ejection fraction: new treatment strategies.
Chrysant SG; Chrysant GS
Hosp Pract (1995); 2019 Apr; 47(2):67-72. PubMed ID: 30712418
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Heart Failure with Preserved Ejection Fraction.
Ilieșiu AM; Hodorogea AS
Adv Exp Med Biol; 2018; 1067():67-87. PubMed ID: 29498023
[TBL] [Abstract][Full Text] [Related]
16. Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction.
Yang M; Kondo T; Adamson C; Butt JH; Abraham WT; Desai AS; Jering KS; Køber L; Kosiborod MN; Packer M; Rouleau JL; Solomon SD; Vaduganathan M; Zile MR; Jhund PS; McMurray JJV
Eur J Heart Fail; 2023 Sep; 25(9):1606-1618. PubMed ID: 37401511
[TBL] [Abstract][Full Text] [Related]
17. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
18. The current best drug treatment for hypertensive heart failure with preserved ejection fraction.
Rist A; Sevre K; Wachtell K; Devereux RB; Aurigemma GP; Smiseth OA; Kjeldsen SE; Julius S; Pitt B; Burnier M; Kreutz R; Oparil S; Mancia G; Zannad F
Eur J Intern Med; 2024 Feb; 120():3-10. PubMed ID: 37865559
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
[TBL] [Abstract][Full Text] [Related]
20. Heart Failure With Preserved Ejection Fraction: A Review.
Redfield MM; Borlaug BA
JAMA; 2023 Mar; 329(10):827-838. PubMed ID: 36917048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
